Risk of malaria in children aged 5 years or more following seasonal malaria chemoprevention or seasonal vaccination discontinuation
| ISRCTN | ISRCTN12207852 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN12207852 |
| Secondary identifying numbers | TMA2019SFP-2834 |
- Submission date
- 21/06/2021
- Registration date
- 02/07/2021
- Last edited
- 02/11/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Malaria is a mosquito-borne infectious disease. Current effective malaria control tools include seasonal malaria chemoprevention (SMC), which is tailored for the countries of the Sahel and Sub Sahel. This strategy involves doses of sulfadoxine-pyrimethamine plus amodiaquine once monthly over the highest malaria transmission period. SMC has the ability to clear a current infection and to prevent the acquisition of a new one. This sustained suppression of the parasite’s presence in the body may slow down the development of an effective immune response to combat the infection. In research studies in which the intervention was given over only a short period of time (no more than two transmission seasons), there was no consistent evidence of this impairment; some studies found a slight effect, whilst others failed to find any. However, in programs in which the intervention is given many times (children born while the intervention is being deployed will receive SMC from the age of 3 months up to 5 years each malaria transmission season without interruption), such crucial information is missing and it is important to evaluate this potential “rebound effect” to alert policymakers to this potential threat as several million children are being treated currently with SMC. To investigate the issue of rebound the researchers will conduct two studies (one for uncomplicated malaria and one for severe malaria). Two community controls will be recruited for each case in the uncomplicated malaria study while two community and two hospital controls will be recruited for each case in the severe malaria study. The participants will all be interviewed with regard to their use of long-lasting insecticide treated nets (LLINs), their socio-economic status, SMC history, and housing. The aim of this study is to determine whether the risk of malaria is higher in children who have had a high level of coverage with SMC compared to those who have not, taking into account any potential confounding factors.
Who can participate?
Children aged 5 years or more, previously enrolled in the seasonal malaria chemoprevention or seasonal vaccination trial
What does the study involve?
The study involves passive surveillance of cases at health facilities. It also involves the recruitment of controls either in the communities or at the health facilities.
What are the possible benefits and risks of participating?
There is no direct benefit of participating in the study. Participants will not be paid to join. However, all participants’ care at the health facility will be paid for by the project. The follow-up at the health facilities involves a finger prick to perform a rapid diagnostic test and a blood smear for malaria diagnosis. This can involve brief pain and the risk of infection is very low as the sampling will be done by experienced staff trained for this purpose.
Where the study is run from?
Institut de Recherche en Sciences de la Santé (Burkina Faso)
When is the study starting and how long is it expected to run for?
July 2021 to December 2024
Who is funding the study?
European and Developing Countries Clinical Trials Partnership (Netherlands)
Who is the main contact?
Issaka Zongo, MD, PhD
zongoissaka08@gmail.com
Contact information
Scientific
Institut de Recherche en Science de la Santé
399 Ave Liberté
Bobo-Dioulasso
226
Burkina Faso
 ORCID ID |
0000-0002-9045-4713 |
|---|---|
| Phone | +226 (0)70636991 |
| zongoissaka08@gmail.com |
Study information
| Study design | Observational study with nested case-control study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Nested case-control study |
| Study setting(s) | Hospital |
| Study type | Prevention |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Risk of malaria in children who have reached the age of 5 years and are no longer eligible for seasonal malaria chemoprevention and or seasonal vaccination in Burkina Faso and Mali |
| Study acronym | SEVR-SMC |
| Study objectives | Children 3-59 months previously submitted to seasonal malaria chemoprevention (SMC) or seasonal vaccination are more susceptible to malaria when the intervention is stopped. |
| Ethics approval(s) | Approved 21/04/2021, National Ethics Committee For Health Research (09 BP 7009, Ouagadougou 09, Burkina Faso; +226 25488937; no email provided), ref: 2021-04-100 |
| Health condition(s) or problem(s) studied | Malaria |
| Intervention | The study is built on a large randomised clinical trial investigating whether combining seasonal malaria chemoprevention (SMC) and seasonal vaccination is better than seasonal malaria chemoprevention and seasonal vaccination alone. This study started on January 2017 and now that children are getting older (aged more than 59 months), they are no longer eligible for SMC or seasonal vaccination. This study will procede by two methods : a) Children aged over 59 months who are no longer receiving SMC will be followed at the health facility to record their medical history and malaria episode from July 1 2021 to December 31 2024. Malaria episodes will be compared between the previous study arm to see whose group is providing more episodes of malaria, b) case control studies. One for uncomplicated malaria and the second for severe malaria. In these case control studies, children presenting at the study clinics with uncomplicated malaria or severe malaria will be recruited as cases. Two community controls will be recruited to match the cases in the uncomplicated malaria case control study while four controls (two communities and two hospital) will be recruited for one severe malaria case. Case controls studies will take place in 2021 (July-Dec 2021) and if any rebound is seen another set of case control studies will be carried out in 2022 (July-Dec). |
| Intervention type | Mixed |
| Primary outcome measure | Incidence of uncomplicated malaria or severe malaria in the year after the interventions are stopped measured using patient records |
| Secondary outcome measures | 1. Incidence of asymptomatic malaria parasitemia at the end of the malaria transmission season in the year after the interventions are stopped measured using patient records 2. Incidence of mild or moderate anemia or of malnutrition at the end of the malaria transmission season in the year after the interventions are stopped measured using patient records |
| Overall study start date | 01/01/2021 |
| Completion date | 31/12/2025 |
Eligibility
| Participant type(s) | Mixed |
|---|---|
| Age group | Child |
| Lower age limit | 59 Months |
| Sex | Both |
| Target number of participants | 5,000 |
| Key inclusion criteria | 1. Belonging to the seasonal malaria chemoprevention or seasonal vaccination cohort and aged over 59 months 2. Provision of signed informed consent |
| Key exclusion criteria | Absence of informed consent |
| Date of first enrolment | 01/07/2021 |
| Date of final enrolment | 31/12/2024 |
Locations
Countries of recruitment
- Burkina Faso
- Mali
Study participating centres
BP/ 545
Bobo-Dioulasso
226
Burkina Faso
Faculty of Pharmacy
University of Science, Techniques and Technology of Bamako
PO Box: 1805 Point G
Bamako
223
Mali
Sponsor information
Research organisation
399 Ave Liberté
BP: 545
Ouagadougou
226
Burkina Faso
| Phone | +226 (0)25 363 215 |
|---|---|
| dirss@fasonet.bf | |
| Website | http://www.irss.bf/index.php?option=com_content&view=frontpage&Itemid=1 |
Funders
Funder type
Research organisation
Private sector organisation / International organizations
- Alternative name(s)
- Le partenariat Europe-Pays en développement pour les essais cliniques, A Parceria entre a Europa e os Países em Desenvolvimento para a Realização de Ensaios Clínicos, The European & Developing Countries Clinical Trials Partnership, European and Developing Countries Clinical Trials, EDCTP
- Location
- Netherlands
Results and Publications
| Intention to publish date | 31/12/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request - zongoissaka08@gmail.com |
Editorial Notes
02/11/2023: The contact confirmed the record is up to date.
24/06/2021: Trial's existence confirmed by EDCTP.
